Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
CLINICAL RESEARCH RESULTS OF A RANDOMIZED, OPEN-LABEL AND PARALLEL-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF HETEROLOGOUS PRIME-BOOST IMMUNIZATION WITH RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) AFTER THREE-DOSE PRIMING WITH AN INACTIVATED COVID-19 VACCINE IN ADULTS AGED 18 YEARS AND ABOVE

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that, the Company has initiated a randomized, open-label and parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), consisting of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation (trade name: Convidecia Air™) and Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia®) after three-dose priming with an inactivated COVID-19 vaccine (CoronaVac) in adults aged 18 years and above, and has received preliminary data.

Clinical Studies and Principal Results

The clinical study was initiated in April 2022 in Jiangsu, with a total of 360 participants enrolled, and long-term follow-up is ongoing. Participants who had received three doses of inactivated vaccine at least 6 months prior were randomized to receive either Convidecia Air™ (the "**Inhalation Group**"), Convidecia® (the "**Intramuscular Group**") or COVID-19 inactivated vaccine (the "**Inactivated Group**") in a ratio of 1:1:1. Each group had approximately 120 participants. All participants had their safety profile evaluated for 28 days post vaccination and immunogenicity assessed on Day 0, 14, 28 and Month 3, 6 post vaccination.

1. Safety

The Inhalation Group had a lower overall incidence of adverse reactions of 9.40% within 28 days post vaccination as compared to the control groups. The severity was mainly mild to moderate, with the incidence of 5.98% and 3.42%, respectively. No Grade 3 adverse reactions occurred. No serious adverse events were reported within 6 months post vaccination. The results demonstrated that Convidecia Air™ has great safety profile as a booster dose to three doses of inactivated vaccine, especially in the elderly population.

2. Immunogenicity

The pre-immunization level of neutralizing antibodies against the SARS-CoV-2 live virus (original strain) was close to negative, while the GMT of neutralizing antibodies in the Inhalation Group reached 672 on Day 28 post booster vaccination, which was higher than 583 in the Intramuscular Group and significantly higher than 59 in the Inactivated Group. The GMT of the Inhalation Group was about 11 times as high as that of the Inactivation Group.

Result of Omicron BA.5 pseudovirus cross neutralization assay showed that, the GMT of Inhalation Group was 108 on Day 28 post-vaccination, which was significantly higher than that of Inactivated Group (GMT:19). 81% of the Inhalation Group participants had an antibody titer ≥ 16, while it was 20% in the Inactivated Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 28, 2022

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.